See the DrugPatentWatch profile for dupixent

Dupixent, a medication used to treat various allergic conditions, experienced significant sales growth in Q4 2020. The regions that primarily drove this growth were the United States and Europe.

In the United States, Dupixent's sales increased by 54% in Q4 2020 compared to the same period in 2019. This growth was primarily driven by an increase in the number of patients being treated with Dupixent, as well as price increases [1].

In Europe, Dupixent's sales grew by 122% in Q4 2020 compared to Q4 2019. This growth was driven by the continued expansion of Dupixent's indications and increased demand in existing markets [1].

It's worth noting that Dupixent's patents are set to expire in 2026 in the US and in 2027 in Europe, which could potentially lead to generic competition and impact sales [2].

In summary, the growth in Dupixent's sales in Q4 2020 was primarily driven by the United States and Europe, with increased demand and expanding indications being the main contributors.

Sources:
[1] "Dupixent Sales Soar in Q4 2020, Driven by US and European Markets." DrugPatentWatch.com, 4 Feb. 2021, [www.drugpatentwatch.com/news/dupixent-sales-soar-in-q4-2020-driven-by-us-and-european-markets/](http://www.drugpatentwatch.com/news/dupixent-sales-soar-in-q4-2020-driven-by-us-and-european-markets/).
[2] "Dupixent (Dupilumab)." DrugPatentWatch.com, [www.drugpatentwatch.com/drugs/dupixent](http://www.drugpatentwatch.com/drugs/dupixent).